IL-36γ Has Proinflammatory Effects on Human Endothelial Cells
Overview
Authors
Affiliations
Interleukin-36 cytokines are predominantly expressed by epithelial cells. Significant upregulation of epidermal IL-36 is now a recognised characteristic of psoriatic skin inflammation. IL-36 is known to induce inflammatory responses in dendritic cells, fibroblasts and epithelial cells. Although vascular alterations are a hallmark of psoriatic lesions and dermal endothelial cells are well known to play a critical role in skin inflammation, the effects of IL-36 on endothelial cells are unexplored. We here show that endothelial cells including dermal microvascular cells express a functionally active IL-36 receptor. Adhesion molecules VCAM-1 and ICAM-1 are upregulated by IL-36γ stimulation, and this is reversed by the presence of the endogenous IL-36 receptor antagonist. IL-36γ-stimulated endothelial cells secrete the proinflammatory chemokines IL-8, CCL2 and CCL20. Chemotaxis assays showed increased migration of T-cells following IL-36γ stimulation of endothelial cells. These results suggest a role for IL-36γ in the dermal vascular compartment, and it is likely to enhance psoriatic skin inflammation by activating endothelial cells and promoting leucocyte recruitment.
The complex roles of IL-36 and IL-38 in cancer: friends or foes?.
Finucane M, Brint E, Houston A Oncogene. 2025; .
PMID: 40057603 DOI: 10.1038/s41388-025-03293-4.
Tertiary lymphoid structures in colorectal cancer.
Lv J, Zhang X, Zhou M, Yan J, Chao G, Zhang S Ann Med. 2024; 56(1):2400314.
PMID: 39575712 PMC: 11616745. DOI: 10.1080/07853890.2024.2400314.
Expanding Role of Interleukin-1 Family Cytokines in Acute Ischemic Stroke.
Matys P, Mironczuk A, Starosz A, Grubczak K, Kochanowicz J, Kulakowska A Int J Mol Sci. 2024; 25(19).
PMID: 39408843 PMC: 11476913. DOI: 10.3390/ijms251910515.
IL-17A-driven psoriasis is critically dependent on IL-36 signaling.
Fischer B, Kubelbeck T, Kolb A, Ringen J, Waisman A, Wittmann M Front Immunol. 2024; 14:1256133.
PMID: 38162658 PMC: 10754973. DOI: 10.3389/fimmu.2023.1256133.
Tertiary lymphoid structures and B lymphocytes: a promising therapeutic strategy to fight cancer.
Esparcia-Pinedo L, Romero-Laorden N, Alfranca A Front Immunol. 2023; 14:1231315.
PMID: 37622111 PMC: 10445545. DOI: 10.3389/fimmu.2023.1231315.